However, acquired resistance to crizotinib monotherapy is well demonstrated in the setting of NSCLC, and a similar phenomenon may arise in ALK-rearranged IMT treated with crizotinib [29]. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.